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Background: Following the spread of the coronavirus disease 2019 (COVID-19)
pandemic a new disease entity emerged, defined as Pediatric Inflammatory Multisystem
Syndrome temporally associated with COVID-19 (PIMS-TS), or Multisystem Inflammatory
Syndrome in Children (MIS-C). In the absence of trials, evidence for treatment
remains scarce.
Schlapbach et al. Recommendations for PIMS-TS in Switzerland
Purpose: To develop best practice recommendations for the diagnosis and treatment of
children with PIMS-TS in Switzerland. It is acknowledged that the field is changing rapidly,
and regular revisions in the coming months are pre-planned as evidence is increasing.
Methods: Consensus guidelines for best practice were established by a
multidisciplinary group of Swiss pediatric clinicians with expertise in intensive
care, immunology/rheumatology, infectious diseases, hematology, and cardiology.
Subsequent to literature review, four working groups established draft recommendations
which were subsequently adapted in a modified Delphi process. Recommendations had
to reach >80% agreement for acceptance.
Results: The group achieved agreement on 26 recommendations, which specify
diagnostic approaches and interventions across anti-inflammatory, anti-infectious,
and support therapies, and follow-up for children with suspected PIMS-TS. A
management algorithm was derived to guide treatment depending on the phenotype
of presentation, categorized into PIMS-TS with (a) shock, (b) Kawasaki-disease like, and
(c) undifferentiated inflammatory presentation.
Conclusion: Available literature on PIMS-TS is limited to retrospective or prospective
observational studies. Informed by these cohort studies and indirect evidence from
other inflammatory conditions in children and adults, as well as guidelines from
international health authorities, the Swiss PIMS-TS recommendations represent best
practice guidelines based on currently available knowledge to standardize treatment of
children with suspected PIMS-TS. Given the absence of high-grade evidence, regular
updates of the recommendations will be warranted, and participation of patients in trials
should be encouraged.
Keywords: child, COVID-19, Kawasaki disease, multisystem inflammatory syndrome, MIS-C, pediatric
inflammatory multisystem syndrome, septic shock
INTRODUCTION
Subsequent to the first wave of the coronavirus disease 2019
(COVID-19) pandemic (1), clusters of children presenting with
unusual multisystem inflammatory conditions emerged (2, 3).
The clinical syndrome showed some heterogeneity with patients
presenting either akin to toxic shock, Kawasaki-disease like or
with undifferentiated inflammatory characteristics, in addition to
evidence of current or past COVID-19 infection in the majority
of cases (4, 5). Accordingly, this new disease entity has been
called Pediatric InflammatoryMultisystem Syndrome temporally
associated with COVID-19 (PIMS-TS) as per the Royal College
of Pediatrics and Child Health case definition (RCPCH) (6) and
Multisystem Inflammatory Syndrome associated with COVID-
19 (MIS-C) as per the Center for Disease Control (CDC) (7) and
the WHO (World Health Organisation) (8).
While a number of studies have attempted to explain the
underlying biological and genetic mechanisms of PIMS-TS,
its pathophysiology and the observed variation in clinical
presentation remains largely unknown (9–11). It is currently
assumed that a complex process involving SARS-CoV-2-specific
antigen presentation to autoreactive T cells, superantigen-
like viral structures, cross-reactive SARS-CoV-2-specific
antibodies and unbalanced cytokine responses may initiate
PIMS-TS in genetically predisposed children (12–16). In other
pediatric hyperinflammatory syndromes, such as Kawasaki
disease (KD), macrophage activation syndrome (MAS), and
hemophagocytic lymphohistiocytosis (HLH), timely initiation of
anti-inflammatory therapy and immunosuppression can often
reverse the hyper-inflammatory state and prevent or mitigate
organ damage. Therefore, therapeutic immune modulation is
widely used as a mainstay of PIMS-TS treatment with the aim
to inhibit cytokine secretion and restore immune homeostasis.
In addition, PIMS-TS patients may also show signs of vasculitis,
endothelial damage, and thrombosis, hence antiplatelet and
anticoagulation management in PIMS-TS represent important
additional considerations (17).
Cardiac involvement includes a supposed post-infectious
myocarditis or myocardial injury and the development of
coronary artery abnormalities with a minority developing
coronary artery abnormalities. Myocardial injury is thought to
be attributed to an acute and dysregulated immune response
related to cytokine storm, endothelial damage, microvascular
dysfunction, and ischemic injury (18). The tropism of SARS-
Cov-2 to myocytes and endothelial cells with the facilitated
entry by binding to the angiotensin-converting enzyme 2
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receptors may contribute to the high percentage of cardiac
involvement (19).
In order to standardize management in Switzerland, we aimed
to develop best practice recommendations for the diagnosis and
treatment of children with PIMS-TS.
STATEMENT OF UNCERTAINTY
At present, professionals remain confronted with substantial
uncertainties regarding clinical phenotypes, long-term
outcomes, and optimal management (20). In the absence of
randomized trials, evidence for best treatment is minimal for the
diagnostic, anti-inflammatory, anti-infectious, and supportive
measures which have been proposed (9, 21). Recommendations
therefore are based primarily on expert opinion and similar
recommendations in the United Kingdom. The field is rapidly
changing with reports being published on an almost weekly basis
(22, 23), hence revision and updates of the recommendations
will be required regularly.
METHODS
Subsequent to a call for Expressions of Interest, the Interest
Group for Pediatric and Neonatal Intensive Care (IGPNI) of
the Swiss Society of Intensive Care Medicine (SSICM) and the
Pediatric Infectious Diseases Group Switzerland (PIGS) formed a
working group on PIMS-TS. In total, 24 panelists across the fields
of pediatric intensive care, infectious diseases, immunology and
rheumatology, hematology, cardiology, and nursing composed
the panel.
Four subgroups focused on the domains of (i) disease criteria
and diagnosis, (ii) anti-inflammatory therapies, (iii) anti-infective
therapies, and (iv) additional support therapies including
coagulation management. Each subgroup performed a focused
literature review on publications since the description of PIMS-
TS in early 2020 until December 2020. In addition, we searched
for available pathways, diagnostic, therapeutic, and follow-up
recommendations from different international institutions (24–
27). Over a period of 5 weeks, weekly virtual meetings of the
entire working group were held to develop and discuss the
recommendations in a modified Delphi process. Finally, voting
was performed by the entire panel for each recommendation
using Survey Monkey. The threshold for recommendations was
met if >80% of panelists voted for full agreement on an item.
The thereby developed guideline was piloted during 4 weeks
in January 2021, subsequent to which an update and re-voting
occurred on items which were agreed to be changed in the panel.
RECOMMENDATIONS
Diagnosis
1. For PIMS-TS, the following case definition should be used:
Adapted RCPCH—case definition (6, 28)
• Patient aged <18 years of age. Persistent fever +
inflammation (elevated CRP and neutrophils, or
lymphopaenia)+ single or multiorgan dysfunction (shock,
cardiac, respiratory, renal, gastrointestinal, neurological)+
additional features (see Table 1). This may include children
fulfilling full or partial criteria for Kawasaki disease (KD).
• Exclusion of any other probable cause, such as bacterial
sepsis, staphylococcal/streptococcal shock syndromes, and
viral infections associated with myocarditis. Waiting for
these results should not delay seeking expert advice.
• Positive for current or recent SARS-CoV-2 infection by
PCR, serology, or antigen test; or COVID-19 exposure
within 4 weeks prior to the onset of symptoms. Waiting for
these results should not delay seeking expert advice.
2. If a child fulfills the diagnostic criteria for PIMS-TS we
recommend classifying these patients according to the
presenting phenotype due to the implications for diagnostic
workup and management:
• Shock-like presentation: signs of shock as per the Goldstein
2005 definition of cardiovascular failure (29) (Appendix)
• Kawasaki disease-like presentation: complete or incomplete
with cardiac involvement, according to AHA (30)
• Undefined inflammatory presentation: persistent pyrexia
with signs of PIMS-TS but not meeting shock criteria nor
having cardiac involvement.
Overall, PIMS-TS remains a rare condition and most children
with SARS-CoV-2 infection will remain asymptomatic or will
exhibit onlymild symptoms (4, 31). Predominant clinical features
include persistent fever and gastrointestinal symptoms, e.g.,
abdominal pain, vomiting or diarrhea. Many patients may exhibit
additional clinical features (Table 1). Cardiovascular impairment
can be manifest at presentation or develop during admission
(18, 32). Coronary artery aneurysms (CAA) may develop post-
discharge up to 3 weeks after disease onset (30). Some patients
show rapid clinical deterioration often characterized by a
vasoplegic shock state requiring admission to intermediate or
intensive care units (IMC/PICU) (4, 33).
It is paramount to avoid anchoring bias given that PIMS-
TS remains a rare condition (34), and in view of the fact that
many children suffering from other disease during the pandemic
may have concomitant microbiological evidence of SARS-CoV-2
exposure. Other, more common differential diagnoses need to be
considered, such as but not restricted to:
– Invasive bacterial infection
– Sepsis
– Toxic shock syndrome (TSS)
– Staphylococcal Scalded Skin Syndrome (SSSS)
– Kawasaki disease (KD)
– Viral myocarditis/infection (such as EBV, CMV, adenovirus,
enterovirus, and other viruses)
– Serum sickness
– Acute appendicitis/acute surgical abdomen
– Gastroenteritis
– Macrophage activation syndrome (MAS) and hemophagocytic
lymphohistiocytosis (HLH) (Appendix)
– Malignant diseases, e.g., acute leukemia.
As pediatric Emergency Departments face large numbers of
febrile children, we recommend a staged diagnostic approach,
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Organ systems Single or multi-organ involvement
Gastrointestinal Abdominal pain, diarrhea, vomiting O
Abnormal liver function tests O
Colitis, ileitis, ascites O
Cardiovascular Hypotension, shock, oliguria O
Myocardial dysfunction, pericardial effusion O
Coronary artery abnormalities O
Respiratory Cough, sore throat O
Oxygen requirement O
Patchy infiltrates, pleural effusion O
Dermatologic Conjunctivitis, periorbital swelling/redness O
Mucus membrane changes O
Rash O
Lymphadenopathy O
Swollen hands and feet O
Neurologic Headache, confusion, irritability, reduced level of consciousness O
Syncope O






Cardiac biomarkers Elevated Troponin T/NT-pro-BNP O
COVID-19 contact Either confirmed or putative O
Confirmed Positive for current or recent SARS-CoV-2 infection by PCR, serology, or
antigen test
O
Putative COVID-19 exposure within the 4 weeks prior to the onset of symptoms O
No alternative plausible diagnosis (microbial or inflammatory) O
Patients must be below 18 years and meet at least one criterion for each group, including (i) presence of fever, (ii) organ involvement, (iii) laboratory evidence of inflammation, (iv)
microbiologically proven or putative COVID-19 contact, and (v) exclusion of other causes.
starting with standard investigations for all children where PIMS-
TS is suspected (Table 2), followed by more in-depth diagnostic
work-up in children with evidence of severe disease, or those with
diagnostic uncertainty.
PIMS-TS may manifest with features of classic or incomplete
(atypical) KD with, or without cardiac involvement (30).
Although the clinical presentation of PIMS-TS patients shares
similarities with KD and TSS (4, 31), there are several differences
in the clinical presentation compared to classical KD and patients
with PIMS-TS by definition lack microbial confirmation of a
staphylococcal or streptococcal infection. Compared to classical
KD, patients with PIMS-TS more often present with prominent
gastrointestinal and neurologic symptoms (18), and the incidence
of cardiac involvement is even higher in PIMS-TS patients. More
than 50% of children with PIMS-TS do develop some sort of
cardiac involvement, defined by elevation of cardiac biomarkers,
systolic or diastolic myocardial dysfunction or even shock. In
addition, there is limited evidence that conduction abnormalities
are more common in PIMS-TS, including heart block (35, 36).
Early involvement of a pediatric multidisciplinary team
(MDT) including intensive care, immunology, infectious
diseases, rheumatology, cardiology, hematology, and others
(e.g., general surgery) should be considered. In addition to
cardiac biomarkers (such as cTnT and NT-pro-BNP) the
cardiac evaluation of a patient with PIMS-TS should include
a 12-lead electrocardiogram and echocardiography (Table 2).
Diagnostic measures, including laboratory tests such as markers
of inflammation and organ dysfunction, and imaging modalities
such as transthoracic Doppler 2D echocardiography should be
repeated sequentially depending on the presentation, disease
severity, and evolution to guide escalation and de-escalation of
therapy, and to rule out other diagnoses.
A substantial proportion of children with PIMS-TS initially
manifest significantly raised levels of NT-pro-BNP and modest
elevations of cardiac troponin, which sometimes take days
to weeks to normalize (19, 32). In patients with preserved
ejection fraction, increased cardiac biomarkers likely reflect
subclinical myocardial injury and may be associated with more
subtle changes in diastolic function (37). Commonly observed
echocardiographic findings include depressed systolic LV and RV
function. Moreover, mitral regurgitation, and mild pericardial
effusion have been described. While most patients show rapid
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TABLE 2 | Recommendations for diagnostic work-up in children evaluated for PIMS-TS.
Baseline investigations in a febrile child
with features of PIMS-TS
(according to disease severity, for a child in
shock baseline and supplementary
investigations should be carried out at the
same time)
Full blood count (FBC)
C-reactive protein (CRP)
Urea, creatinine, electrolytes (U&E)
Liver function tests (LFTs)
In addition, as clinically indicated:
– Blood cultures (always before starting antibiotics)
– Urine microscopy and culture
– Lumbar puncture, if no contraindication present
– NPA: respiratory panel, SARS-CoV-2 PCR
Supplementary investigations in case of
suspected PIMS-TS
(in addition to baseline investigations)
Blood gas, lactate, glucose
Erythrocyte sedimentation rate (ESR)









Store serum (always before starting IVIG)
Store EDTA
12-lead ECG and echocardiography
Chest radiograph
Abdominal ultrasound (if gastrointestinal symptoms)
Other optional extended investigations
(according to clinical presentation after MDT
discussion. Those should NOT delay seeking
expert opinion or treatment)





*consider full HLH screen if suggestive features present (e.g., splenomegaly, fibrinogen normal or low; ferritin >2,000
µg/l): Perforin-, SAP-, and XIAP-expression, NK cell degranulation and consider HLH-directed therapy (MDT)
Repeat investigations: Critical patient (deteriorating and/or in PICU):
Approx. 24 hourly: FBC, CRP, U&E, LFTs, coagulation, ferritin
Other parameters guided by clinical progress
Cardiac biomarkers, echocardiography in consultation with cardiology, ECG
Non-critical patient with ongoing pyrexia:
24–48 hourly: FBC, CRP U&E, LFTs, ferritin
*as above
Echocardiography 48 hourly (in consultation with cardiology)
Child improving ± defervescence:
48 hourly or pre-discharge: FBC, CRP, U&E, LFTs, ESR
Consultation with cardiology prior to discharge
Where possible, PIMS-TS patients should be enrolled in observational or interventional studies, which may include additional diagnostics.
*Children with evidence of cardiac involvement should be discussed with a tertiary center for cardiology involvement and care in PICU should be considered.
improvement in LV systolic function and even normalization
within 1–2 weeks after initial presentation, diastolic dysfunction
often persists until early follow up or longer (37).
ECG registration is recommended at the time of diagnosis
and every 48 h while inpatient, daily in patients on PICU.
Most ECG findings are non-specific and include ST-segment
changes, QTc prolongation and premature atrial or ventricular
beats. Another common finding is first-degree (rarely higher
grade) atrioventricular block—which may progress after initial
diagnosis (35, 36). Single cases of atrial fibrillation or sustained
arrhythmias leading to hemodynamic collapse have been
described (38). All inpatients should be monitored by telemetry.
In well patients with unremarkable ECG recording, oxygen
saturation and heart rate monitoring is deemed to be sufficient.
In outpatients with first-degree atrioventricular block or
arrhythmias Holter monitoring is recommended (27).
Coronary artery aneurysms represent a serious complication
and may place patients at risk for coronary artery thrombosis
or stenosis, myocardial infarction and cardiac death. Coronary
artery abnormalities have been reported to appear in 8–24% of
patients with PIMS-TS irrespective of the phenotype (18, 32).
Most of them are dilation or small aneurysms, but large/giant
aneurysms may occur (38), even during the convalescent period
(4, 39). While, coronary artery dilation resolve within 4–8 weeks
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FIGURE 1 | PIMS-TS diagnostic and therapeutic algorithm.
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TABLE 3 | Anti-inflammatory therapies in patients with PIMS-TS.
Class Drug Route Dose Duration Comments and side effects
Blood products IVIG IV 2 g/kg (max 100g) Infusion over
12 h
Side effects: Aseptic meningitis, volume load, systemic
inflammation, hemolytic anemia, neutropenia. Slower the
rate or divide the dose over 2 days if signs of volume
overload or severe cardiac dysfunction
Corticosteroids Methylprednisolone IV 2 mg/kg daily (max 60
mg/day) or 10 mg/kg




Side effects: Hyperglycemia, hypertension, agitation
Note: dose increase up to 30 mg/kg can be considered
if refractory
Prednisolone PO 1 mg/kg q12 h or 2
mg/kg q24 h (max 60
mg/day)





SC start at 2–3 mg/kg
q12 h (max. 100
mg/dose)
Discuss in MDT Escalation/taper: MDT decision. IV administration
possible under different dosing scheme.
Side effects: neutropenia, leukopenia,
thrombocytopenia, eosinophilia, headache, abdominal
pain, nausea/vomiting, diarrhea, hepatitis, increased
serum transaminases, hypersensitivity reactions,




IV <30 kg: 12 mg/kg
single dose (max
800mg)
≥30 kg: 8 mg/kg single
dose (max 800mg)
Discuss in MDT Escalation: If no clinical improvement after initial dose,
may repeat dose 8–12 h after the initial dose after MDT
discussion.
Side effects: neutropenia, leukopenia,
thrombocytopenia, anemia, pain, headache, dizziness,
insomnia, demyelinating disorders, ulcerations, nausea,
increased serum transaminases, liver impairment,
increase in serum lipids, pancreatitis, hypertension,
hypothyroidism, hypersensitivity reactions,
Steven-Johnson-Syndrome, conjunctivitis,
nephrolithiasis, injection-site reactions, rash
Infliximab
(chimeric tumor
necrosis factor TNF α
monoclonal antibody)
IV 5 mg/kg single dose Discuss in MDT Side effects: neutropenia, leukopenia/agranulocytosis,
thrombocytopenia, anemia, pain, headache, dizziness,
insomnia, demyelinating disorders, hypersensitivity
reactions, injection-site reactions, skin rash
Data were accessed from www.accessdata.fda.gov/, www.ema.europa.eu/, and the British Pediatric Allergy, Immunity, and Infection Group [Position Statement: Management of novel
coronavirus (SARS-CoV-2) infection in pediatric patients in the UK and Ireland] and adapted from the Imperial College Healthcare NHS Trust PIMS-TS guideline for external use. MDT,
multidisciplinary team; IVIG, intravenous immunoglobulins.
Disclaimer: Medication dosing and administration should be checked with the local hospital pharmacists and considering recent evidence updates. Where possible, PIMS-TS patients
should be enrolled in interventional studies.
without sequelae, aneurysmsmay lead to coronary artery stenosis
and thrombosis even when they reduce in size over weeks to
months (30).
Anti-inflammatory Therapies
3. Therapeutic immune-modulation in PIMS-TS patients
requires a multidisciplinary approach. Clinicians should
re-evaluate the patient response and consider differential
diagnoses at every step.
We recommend a MDT approach to guide initiation,
escalation, and tapering of empiric immunomodulatory
therapy, particularly because available evidence for such
treatment is currently only based on observational reports.
The panel recommends using a management algorithm
(Figure 1) to guide the step-wise selection of the initial
interventions. Dosing recommendations are provided in
Table 3 and were adapted from the Imperial College Healthcare
NHS Trust PIMS-TS guideline (Prof. Elizabeth Whittaker,
personal communication).
4. In patients with Kawasaki disease-like PIMS-TS,
immunomodulation and management should follow
established guidelines for Kawasaki disease.
5. In patients with PIMS-TS shock, we recommend using
immunoglobulins (IVIG, 2 g/kg).
6. In patients with PIMS-TS shock we recommend treatment
with intravenous pulse high-dose methylprednisolone (10
mg/kg q24 h for 1–3 days, max. 1 g/day).
7. In non-shocked patients with PIMS-TS undefined
inflammatory presentation clinicians should consider
administration of immunoglobulins (IVIG, 2 g/kg).
8. In non-shocked patients with PIMS-TS (Kawasaki-like
presentation or undefined inflammatory presentation)
clinicians should consider administration of prednisolone (2
mg/kg q24 h, max. 60 mg/day).
9. In all patients with confirmed PIMS-TS treated with steroids,
steroids should be tapered over a period of 2–6 weeks
depending on the clinical course and considering the
clinical and biochemical (such as CRP, D-Dimer, and ferritin
levels) response.
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For children with Kawasaki disease-like PIMS-TS and for
children with coronary artery abnormalities irrespective of the
PIMS-TS phenotype, the panel recommends that established
institutional or international guidelines such as the 2020
American College of Rheumatology guidelines (40) on Kawasaki
disease-like PIMS-TS should be followed. In addition, both
the European SHARE initiative (41) and the American Heart
Association guidelines (30) provide guidance on KD.
We recommend, based on currently available reports and
in line with other recommendations, to use intravenous
immunoglobulin (IVIG) in PIMS-TS patients presenting with
shock, and to consider IVIG in PIMS-TS with undefined
presentation. While IVIG should be usually administered as a
single dose of 2 g/kg (max. 100 g/dose), clinicians should assess
the cardiac and fluid status, particularly in patients in shock, as in
some patients a slower administration become necessary.
While corticosteroids have often been used as adjuncts
to IVIG (42), the specific indication, dosing, timing or type
of glucocorticoids in PIMS-TS remains unknown. A French
propensity-matched study of 111 children with PIMS-TS
reported substantially improved outcomes in children with
PIMS-TS treated with IVIG and steroids (9% persistence of
fever) in comparison to children who received IVIG alone
(51% treatment failure, Odd’s ratio 0.25; 95%-CI 0.09–0.70,
p-value 0.008) (43). The panel considered that benefit vs.
harm justify pulse high-dose steroids for a duration of 1–
3 days in PIMS-TS patients with shock, with an initial dose
of 10 mg/kg methylprednisolone (max 1 g/day). Increasing
the methylprednisolone dose to 30 mg/kg q24 h may be
considered, although side effects such as hyperglycemia,
hypertension, agitation, hospital-acquired infection, and hip
osteonecrosis should be weighed against potential benefit. PIMS-
TS patients treated with pulse corticosteroids should receive
gastric protection with proton-pump inhibitors.
Given potential side effects and the lack of data, we advise
against the use of pulse steroids in PIMS-TS patients without
shock but suggest considering a lower dose therapy given
intravenously (up to 2 mg/kg/day) and, subsequently, orally.
While the optimal duration of steroid therapy in PIMS-
TS remains unknown, the joint view of the panel is that
decisions on steroid treatment duration should be guided by
the clinical response (resolution of signs and symptoms), as
well as by laboratory evidence of decreasing inflammation and
improving organ function. Most patients seem to recover well
under a 14-day treatment schedule without subsequent signs of
disease rebound. In patients with apparent rebound, alternative
inflammatory diagnoses should be considered.
A proportion of patients may not respond to initial treatment,
and deterioration of the disease can be life-threatening.
Refractory PIMS-TS is characterized by persistent fever and/or
increase of inflammatory markers, worsening organ function, or
increase in need of vasoactive drugs [measured by Vasoactive-
Inotrope Score (44)] within 24–48 h after start of treatment.
Consideration of disease severity in particular in PICU patients,
and assessing evidence of persistent or progressive (multi-) organ
dysfunction is paramount to guide treatment escalation.
Again, MDT assessment is recommended and needs to
take differential diagnoses into account at every step before
escalating treatment, and should carefully evaluate risk-vs.-
benefit ratio of escalating immunomodulatory therapies. For
example, PIMS-TS patients may develop secondary infections
and immuno-suppressive treatment regimensmay further impair
the host defense against infection. The current list of biological
drugs includes IL-1R (i.e., anakinra), IL-6R (i.e., tocilizumab)
and tumor necrosis factor (TNF) (infliximab) blocking agents
(Table 3). In addition, clinicians may discuss administration of
a second dose of IVIG, or pulse steroids.
10. In patients with PIMS-TS refractory to initial treatment with
IVIG and steroids, and after exclusion of alternative causes
by the multidisciplinary team, we suggest consideration for
anakinra. We recommend starting at 2–3 mg/kg q12 h s.c.
(max. 100 mg/dose, total of 4–6 mg/kg/day). In case of
clinical improvement, stopping of anakinra after 48–72 h
should be considered in the multidisciplinary team.
11. In patients with PIMS-TS where no clinical and biochemical
improvement to anakinra treatment is observed within
24–48 h, the multidisciplinary team should consider
other targeted immunomodulation therapy with either
tocilizumab or infliximab.
12. Clinical assessment and serial laboratory testing on
measures of inflammation and organ dysfunction should
guide escalation and duration of immunomodulation
therapy treatment.
Despite its limited licensed indication, anakinra is increasingly
chosen for off-label use in PIMS-TS patients (4, 45–47). Anakinra
has been approved for subcutaneous administration, however
continuous intravenous administration has been reported (48).
Its short half-life (4–6 h) (Table 3), allows for repeated re-
assessment of the immunosuppressive regimen. We therefore
suggest a short trial of IL-1R blockade in PICU-hospitalized
PIMS-TS patients that have not responded within a period of
24–36 h following administration of both IVIG and steroids.
Anakinra dose increase in the absence of clinical improvement
may be considered in the MDT. We suggest stopping
anakinra after 48–72 h without tapering in case of clinical
improvement. There is no evidence to support routine serial
cytokine level assessment to guide cytokine-targeted therapy
(CTT) (49).
Tocilizumab is an IL-6R blocking agent currently approved
for the treatment of both systemic and polyarticular juvenile
idiopathic arthritis in children above 2 years of age. Tocilizumab
has also been used in children with PIMS-TS as IL-6 has been
described to be one of the main drivers of the inflammatory
cytokine storm in this disease entity. However, safety concerns
exist as significant side effects have been described such as a
reversible elevation of liver enzymes and an increased risk for
bacterial and fungal infections (Table 3). Therefore, tocilizumab
should be reserved for children with life-threatening PIMS-TS
in whom anakinra has failed to show a clear benefit within 48 h.
Given the long half-life (150 h) tocilizumab is usually given as a
single intravenous dose.
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The TNF-alpha blocking agent infliximab, classically used
in children with various autoimmune inflammatory diseases
has also been successfully used in children with KD. However,
since infliximab increases the risk for secondary infections, and
based on its long half-life (around 8 days, Table 3), infliximab
should be administered as a single intravenous dose, and only
in patients with PIMS-TS who failed to respond to anakinra
(or tocilizumab).
Anti-infective Therapies
13. Based on the absence of evidence of remdesivir treatment for
children with COVID-19 and the proposed post-infectious
concept of PIMS-TS (50) we do not recommend the routine
administration of remdesivir in PIMS-TS patients.
14. Children with suspected PIMS-TS and signs of shock
or other organ dysfunction should be treated empirically
with intravenous broad-spectrum antimicrobial therapy for
bacterial sepsis.
15. In children with PIMS-TS receiving intravenous
antimicrobial therapy, we recommend daily assessment
(e.g., clinical, laboratory assessment) for de-escalation
of antimicrobial therapy in consultation with infectious
diseases specialists. Stopping of antimicrobial therapy
should be considered depending on the clinical course,
microbiological findings, and the presence of PIMS-TS
diagnostic criteria, including evidence of recent or current
SARS-CoV-2 infection by serology or PCR.
Remdesivir, a nucleoside analog prodrug, has been approved
for the treatment of COVID-19 in adults based on emerging
evidence demonstrating the efficacy in shortening time to clinical
recovery (51, 52), however recent experience (51, 53) has
not confirmed these findings. The safety and effectiveness of
remdesivir for treatment of COVID-19 in children has not
yet been evaluated (studies are underway) outside case reports
(54, 55). Hence the role of remdesivir in the management of
PIMS-TS is uncertain, especially as PIMS-TS represents a post-
infectious disorder rather than active SARS-CoV-2 infection.
For these reasons the panel agreed that remdesivir should not
be routinely used in children with PIMS-TS. However, PIMS-
TS patients may be considered for the compassionate use of
remdesivir on a case-by-case basis (31, 56). When remdesivir is
used the FDA emergency use authorization instructions for the
use of remdesivir in children >3.5 kg should be followed (57).
Children with PIMS-TS initially often present with signs
and symptoms that mimic those of septic shock and toxic
shock syndrome (34) and neither clinical findings (fever,
rash, abdominal symptoms), infection markers (CRP), nor
other laboratory measures of inflammation may allow reliable
discrimination (58, 59). Mortality in children with sepsis
and septic shock increases as time to effective antimicrobial
therapy increases (60, 61). All suspected PIMS-TS patients with
clinical signs of sepsis should therefore receive prompt empiric
intravenous antibiotics within 1 h of presentation for those with
shock, and within up to 3 h for those without shock (60). The
choice of antibiotics should be based on local guidelines and
taking into account age, epidemiology, signs consistent with toxic
shock, and pre-existingmedical conditions. Antibiotics should be
stream-lined or stopped on the basis of the clinical course and
microbiological culture results in discussion with the infectious
diseases team.
Supportive Measures
16. All PIMS-TS patients with shock or other organ dysfunction
must be transferred to a center with availability of
specialized Pediatric Intensive Care Units, cardiology,
infectious diseases, and immunology/rheumatology.
17. Hemodynamic, respiratory, and other organ support
should follow established guidelines such as the Surviving
Sepsis Campaign.
18. Extracorporeal Membrane Oxygenation should be
considered in PIMS-TS with cardiac, respiratory, or
cardiorespiratory failure refractory to conventional
management as per established guidelines such as the
Surviving Sepsis Campaign.
Many PIMS-TS patients do not show evidence of active viral
infection and may be less likely to be infectious to healthcare
workers. However, clinical staff should wear appropriate personal
protective equipment (31) as per institutional guidelines.
Children should be triaged, assessed and management in line
with recommendations for management of fever in infants <36
months, Surviving Sepsis Campaign (60), and standard Pediatric
Advanced Life Support resuscitation algorithms for critically ill
children. As some children’s condition may worsen rapidly and
they may develop hemodynamic compromise, close monitoring
and early referral to a center with expertise in pediatric cardiology
and PICU is mandatory. During resuscitation with fluid boluses,
repeated assessment for signs of fluid overload is warranted (58)
given risks associated with fluid overload, and considering that
myocardial involvement is often seen in PIMS-TS.
19. In the absence of contraindications, we recommend starting
prophylactic i.v. unfractionated heparin at a dose of 10
U/kg/h in PIMS-TS patients with shock. Conversion to low
molecular weight heparin (LMWH, such as enoxaparin at
a dose of 0.5 mg/kg q12 h) after the first day should be
considered, depending on renal function.
20. In any other PIMS-TS patient requiring intensive care
admission, we recommend prophylactic heparin (at a dose of
10 U/kg/h) or low molecular weight heparin (LMWH, such
as enoxaparin at a dose of 0.5 mg/kg s.c. q12 h) depending on
renal function.
21. For PIMS-TS patients not requiring PICU care, individual
risk factors for thrombotic complications should be assessed
to guide decisions on individualized anticoagulation therapy.
22. In all patients with coronary artery abnormalities antiplatelet
management should follow established guidelines for
Kawasaki disease.
23. As all patients with PIMS-TS irrespective of their phenotype
are at risk for coronary artery aneurysms it is reasonable to
administer low-dose acetyl salicylic acid (3–5 mg/kg, max.
100mg) in all patients at least for 4–6 weeks until coronary
abnormalities have been ruled out.
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While there are only scarce data on the use of anticoagulation
in children with PIMS-TS (40), there seems to be an increased
risk of thromboembolic complications in patients infected
with COVID-19, and as well during acute PIMS-TS (17, 62).
These risks may potentiate the baseline risk of thromboembolic
complications in critically ill children exposed to central venous
devices, immobility, and other procedures (63). Therefore, the
panel suggested to use prophylactic anticoagulation in those
patients of higher severity requiring PICU admission. Clinicians
should always weigh benefit of antiplatelet and anticoagulation
treatments against the individual risk for clinically relevant
bleeding. In acutely critically ill patients with shock the clinical
course may rapidly change. For this reason we suggest starting
with heparin rather than LMWH to enable stopping or reversal if
clinically relevant bleeding occurs, and to avoid accumulation if
renal function deteriorates.
In non-PICU patients, the overall assessment of the individual
risk profile should include well-established risk factors such as
a previous history of venous thromboembolism or a first-degree
relative with venous thromboembolism, the presence of a central
line, post-pubertal age or estrogen therapy amongst other. In
addition, obesity may increase risk for thromboembolic events
in patients with SARS-CoV-2 infection or PIMS-TS.
Similar to classical KD patients, children with PIMS-TS
irrespective of the phenotype may be at risk for the development
of coronary artery aneurysms. Hence it appears to be reasonable
to consider low dose aspirin (3–5 mg/kg, maximum 100mg,
q24 h) in addition to prophylactic anticoagulation in all patients
with PIMS-TS.
DISCHARGE FROM HOSPITAL AND
PROPOSED FOLLOW-UP
24. Patients who have been clinically well on regular wards
with evidence of normal or recovering cardiac function, and
who have been afebrile (<38 degrees) for 48 h should be
considered for discharge home after MDT review.
25. A multi-disciplinary follow up is recommended for
all patients at least after 1–2 weeks, and 4–6 weeks,
respectively, post discharge from hospital. Follow-up
should include pediatric immunology/rheumatology and
cardiology, and, depending on the presentation and severity,
other disciplines.
26. In case of cardiac involvement, cardiac follow up should be
performed at least at 3, 6, and 12 months after discharge
(Table 4).
Hospitals who do not have access to pediatric immunology,
cardiology, or intensive care services should consult with
the respective centers. In all children with PIMS-TS
irrespective of the phenotype, consultation with cardiology is
recommended before discharge to guide frequency of follow-up
echocardiographic assessment, as cardiac function may not have
fully normalized by the time of discharge and aneurysms may
develop later in the course of the disease, even post-discharge. In
general, we suggest performing a follow-up visit 1–2 weeks, and
4–6 weeks, respectively, after discharge which should encompass
a multidisciplinary consultation. The visits should serve as well to
critically review the indication, dosing, and duration of ongoing
immunosuppressive therapy as appropriate. There is no evidence
on duration and tapering schedules of steroids in PIMS-TS,
nor on the recommended duration of hospitalization. Decisions
on post-discharge treatment thus should be guided by ongoing
laboratory or clinical evidence for persistent inflammation.
In children with cardiac manifestations, extension of the
follow-up is recommended, and specific cardiac follow up is
dependent on the degree of initial cardiac involvement, persistent
myocardial dysfunction, coronary artery abnormalities, or
rhythm disturbances. For all patients with coronary artery
abnormalities a cardiologic follow up according to the American
Heart Association KD guidelines is recommended (30). Hence,
careful follow up should be considered to monitor myocardial
function and coronary artery changes. Table 4 provides a
suggestion on follow-up but it is important to acknowledge the
lack of data to inform best follow-up practice at the present stage.
Exercise restriction is recommended for 2 weeks from
discharge if there is no cardiac involvement; for 3–6 months if
cardiac involvement was documented. ECG, echocardiography,
exercise stress test and Holter monitor should be performed
before resuming sport activity and cTnT andNT-pro-BNP should
be normalized (27).
DISCUSSION
Within months of the COVID-19 pandemic spread, many
countries across the globe have reported children presenting
unwell with features of severe inflammation and multisystem
disease (64, 65). Using available literature and guidelines from
international institutions, the Swiss PIMS-TS recommendations
represent best practice guidelines based on currently available
knowledge to facilitate and standardize treatment of children
with suspected PIMS-TS in Switzerland. The available literature
is limited to retrospective and prospective studies from
different part of the world (66, 67). There are no trials
comparing different treatment modalities. The guidance on
using various immunomodulatory agents is therefore limited
to data from these observational cohort studies and indirect
evidence from other hyperinflammatory conditions in children
and adults.
These recommendation were established in exchange
with experts from the U.K. and, accordingly, leverage from
the RCPCH case definition. In comparison to another
recently published institutional protocol on PIMS-TS
from New York (26), our algorithm stratifies by severity
defined as shocked/non-shocked rather than using specific
vasopressor thresholds which are usually not applicable
outside the intensive care environment. For children
without shock presenting with undifferentiated PIMS-
TS presentations, IVIG should be considered by the
MDT team.
A number of limitations need to be considered. First, while
the expert group includes specialists from the relevant disciplines,
numbers of children with PIMS-TS during the first wave of









































TABLE 4 | Proposed recommendations for clinical follow-up of PIMS-TS patients post-discharge.
Time since hospital discharge
Initial cardiac involvement (at
diagnosis or during hospitalization)
1–2 weeks 4–6 weeks 3 months 6 months 12 months Exercise
restrictiona
General notes













Consider stopping follow-up at 4–6 weeks
in patients without Kawasaki-like
presentation; If coronary abnormalities at
any time during follow-up => follow AHA
KD guidelines 2017 [see (5) below]
2 weeks Consider involvement of
other specialities if initial
and/or persistent organ
system abnormalities
No live vaccines for 11
months following
high-dose IVIG (2 g/kg)
(2) Myocardial injury (elevated cTnc ±
NT-pro-BNP), normal ventricular
function and normal coronary arteries
or
(3) Myocardial injury with initially
depressed ventricular function,
normalized systolic function at hospital































(4) Myocardial injury with persistent















Follow-up and sport restriction should be
tailored based on the severity of the
cardiac involvement and in line with
guidelines for heart failure and myocarditis
in children.









ASS, acetylsalicylic acid; BP, blood pressure; CRP, C-reactive protein; Echo, echocardiography.
a24 h-ECG and exercise stress test should be performed before returning to sports activity.
bConsider 24 h-ECG if symptoms of arrythmia or abnormal ECG.
cLaboratory investigations should include FBC, inflammatory markers (CRP) and cardiac enzymes (CK, CK-MB, cTnC, NT-pro-BNP) as well as other values not normalized at hospital discharge (such as coagulation, U/E, LFTs). Also
consider performing urine testing if previously abnormal or signs of renal abnormalities.
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COVID-19 in Switzerland were low, limiting experience in
managing the disease (14, 45). However, the group assessed
institutional pathways from other health care systems and
consulted world leading experts in the field during the process.
Second, the literature review performed was not systematic but
focused. Third, to date there are no published results from
randomized controlled trials in the field, and the evidence base
for optimal PIMS-TS management remains minimal. Finally,
recommendations were issued in the context of a well-resourced
setting, where IVIG and biologicals are relatively easily available,
and may not be applicable to resource limited settings. In relation
to applying these guidelines, clinicians should be mindful of the
risk of anchoring bias during the pandemic. Many children may
test positive for COVID-19, not necessarily implying causality.
The CDC, WHO and RCPCH case definitions of PIMS-TS bear
a risk to over diagnose an assumedly rare syndrome in children
who suffer from other common infectious or inflammatory
or conditions such as septic shock, or rarer conditions such
as HLH.
In conclusion, it is imperative that children with PIMS-
TS are enrolled in prospective trials where feasible (68–70),
and that clinical data are collected and shared to improve our
understanding of the disease and its best management. Given
the absence of high-grade evidence (20), regular revisions of
these recommendations will be required when more evidence
becomes available.
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